Skip to content
Govbase
Govbase
Congress·In Committee·H.R. 1117

Congress moves to block consumer ads for newly approved drugs for 3 years, with limited waiver option

Responsibility in Drug Advertising Act of 2025

about 1 year ago·View on Congress.gov
⏸

Stalled

No legislative action in over 90 days.

Legislative Progress

House
Senate
President
Law

Key Points

  • Congress would ban drug makers from advertising newly approved prescription drugs directly to the public for the first 3 years after approval, including on social media.
  • A drug company could ask for a limited waiver in the third year, but only if federal health officials decide the ads would help public health.

    From policy text

    “The Secretary may waive the application of subparagraph (A) to a drug during the third year of the 3-year period described in such subparagraph if-- ``(i) the sponsor of the drug submits an application to the Secretary pursuant to subparagraph (C); and ``(ii) the Secretary, after considering the application and any accompanying materials, determines that direct-to-consumer advertising of the drug would have an affirmative value to public health.”
    View in full text
  • After the first 3 years, federal health officials could still block consumer ads for a drug if new safety problems show up after people start using it more widely.
  • The bill tells federal health officials to update the rules for drug ads within 1 year after the law is enacted.

    From policy text

    “Not later than 1 year after the date of the enactment of this section, the Secretary shall revise the regulations promulgated under this Act governing drug advertisements to the extent necessary to implement this section.”
    View in full text
  • For everyday people, this could mean fewer “ask your doctor about…” ads for new drugs, and more time for safety issues to be spotted before heavy marketing starts.
HealthcareConsumer ProtectionPrescription Drugs

Impact Analysis

Personal Impact

How this policy affects specific groups of people

Mixed Impacts(1)
Chronic Illness
Neutral

Milestones

2 milestones2 actions
Feb 7, 2025House

Referred to the House Committee on Energy and Commerce.

Feb 7, 2025

Introduced in House

What Happens Next

Projected impacts based on AI analysis

Within 1 year after the bill becomes law

FDA updates its drug advertising rules to carry out the new limits

You may start seeing clearer enforcement around which prescription drugs can be advertised to the public, especially online and on social media

Starting after the bill becomes law, for drugs covered by the effective-date rule

New 3-year ad blackout starts for newly approved drugs (with a possible waiver late in year 3)

Brand-new prescription drugs would generally not be marketed directly to you through ads during their first 3 years on the market

Any time after the first 3 years, if safety evidence supports it

FDA can block ads even after year 3 if serious safety problems show up

If a drug later appears to have major harmful side effects, you might stop seeing ads for it even if it has been on the market for years

Source Information

Document Type

Congressional Bill

Official Title

Responsibility in Drug Advertising Act of 2025

Bill NumberHR 1117
Congress119th Congress
ChamberHouse of Representatives
Latest ActionReferred to the House Committee on Energy and Commerce.

Sponsor

Analysis generated by AI. Always verify with official sources.